-
Sector Analysis
NHS England's Plans to Optimize Cost-Effectiveness of New Weight Loss Drugs, Including Phased 12-Year Model for Mounjaro
National Health Service (NHS) England has pioneered a novel 12-year trial scheme to help ensure cost-effective reimbursement of Eli Lilly's (US) innovative weight loss drug Mounjaro (tirzepatide) to NHS patients, by prioritizing those most in need and evaluating several possible provision models in parallel in patients with the greatest need before expanding to a broader population.
-
Product Insights
Stroke Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Stroke - Global Clinical Trials Review, 2025" provides an overview of Stroke Clinical trials scenario. This report provides top line data relating to the clinical trials on Stroke. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Seborrheic Keratosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Seborrheic Keratosis - Global Clinical Trials Review, 2025" provides an overview of Seborrheic Keratosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Seborrheic Keratosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2025 Update
GlobalData's clinical trial report, “Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura - Global Clinical Trials Review, 2025" provides an overview of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura Clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
Alopecia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Alopecia - Global Clinical Trials Review, 2025" provides an overview of Alopecia Clinical trials scenario. This report provides top line data relating to the clinical trials on Alopecia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Polycystic Kidney Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Polycystic Kidney Disease - Global Clinical Trials Review, 2025" provides an overview of Polycystic Kidney Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Polycystic Kidney Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Myelodysplastic Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Myelodysplastic Syndrome - Global Clinical Trials Review, 2025" provides an overview of Myelodysplastic Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Myelodysplastic Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Diabetic Nephropathy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Diabetic Nephropathy - Global Clinical Trials Review, 2025" provides an overview of Diabetic Nephropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Obesity in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2031
This report covers the 68 geographical markets and provides an Excel-based forecast model for the obesity market through 2031. Across the 68 markets, sales in the obesity market were $12.3 billion in 2021, growing to $206.5 billion in 2031. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 85% and 84% of 68-market sales in 2021 and 2031, respectively.
-
Thematic Analysis
United States (US) Elections 2024 - Executive Briefing (Third Edition) - Strategic Intelligence
Reasons to Buy the ‘US Elections′ executive briefing report: This report discusses how the key policies of President Trump, especially tariffs, will impact the US and global economy. It explores his likely policies and what their impact will be. It explores the sectors that will potentially be most impacted, including energy and automotive. How is this report unique from other reports in the market? The report focuses on: Five policy areas with wide-ranging economic and business impacts and where the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.